Coherus Oncology to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will be presenting during upcoming conferences. The presentations will be accessible via webcast through a link posted on the Investor Events Calendar section of the Coherus Oncology website: https://investors.coherus.com/events-presentations. A replay of the presentation will be available on this same website for approximately 90 days.

GlobeNewsWire • Feb 23, 2026

Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock

–The Offering was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Healthcare Investments and Samsara BioCapital–

GlobeNewsWire • Feb 17, 2026

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced the pricing of an underwritten public offering of 28,600,000 shares of the Company's common stock (the “Offering”). The shares of common stock are being sold at a public offering price of $1.75 per share, before underwriting discounts and commissions. All of the shares in the Offering are being sold by the Company. The gross proceeds to Coherus from the Offering are expected to be approximately $50.1 million, before deducting underwriting discounts and commissions and other offering expenses. The Company has granted the underwriters of the Offering a 30-day option to purchase up to an additional 4,290,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. The Offering is expected to close on or about February 17, 2026, subject to the satisfaction of customary closing conditions.

GlobeNewsWire • Feb 13, 2026

Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 13, 2026

Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 10:30 a.m. Pacific Time. The presentation and Q&A session will be accessible via webcast through a link posted on the Investor Events Calendar section of the Coherus website: https://investors.coherus.com/events-presentations.

GlobeNewsWire • Jan 6, 2026

Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)

-Coherus Oncology formally introduces non-proprietary name:  tagmokitug- -Publication shows picomolar affinity for CCR8 with no off-target binding and proof-of- mechanism in preclinical and clinical studies- -Data show CCR8 target is present with high prevalence and density in many solid tumors- REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced the publication of preclinical and clinical biomarker research in Molecular Cancer Therapeutics describing the high selectivity, picomolar binding affinity and significant effector mediated killing of CCR8+ cells of its investigational anti-CCR8 monoclonal antibody.

GlobeNewsWire • Jan 5, 2026

Coherus Oncology: A Two-Pronged March With Mid-2026 Implications

Coherus Oncology maintains a 'Buy' rating, driven by a promising clinical pipeline and undervaluation relative to cash and equity holdings. CHRS's commercial growth is anchored by toripalimab sales in a niche U.S. indication, but profitability hinges on pipeline success. Key catalysts include mid-2026 data readouts for casdozokitug and CHS-114; no major Q1 2026 milestones are expected.

Seeking Alpha • Dec 23, 2025

Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

-6 Years Long-term survival data reinforce potential benefit to patient survival in treating recurrent or metastatic nasopharyngeal carcinoma with LOQTORZI in combination with chemotherapy - -6 Years Long-term survival data reinforce potential benefit to patient survival in treating recurrent or metastatic nasopharyngeal carcinoma with LOQTORZI in combination with chemotherapy -

GlobeNewsWire • Dec 8, 2025

Coherus Oncology, Inc. (CHRS) Presents at UBS Global Healthcare Conference 2025 Transcript

Coherus Oncology, Inc. ( CHRS ) UBS Global Healthcare Conference 2025 November 10, 2025 1:15 PM EST Company Participants Dennis Lanfear - Chairman, President & CEO Theresa Lavallee - Chief Development Officer & Chairman of Scientific Advisory Board Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Xiaochuan Dai UBS Investment Bank, Research Division Excellent. Great. Well, thank you, everyone, for joining us, joining our fireside chat with Coherus.

Seeking Alpha • Nov 10, 2025

Coherus Oncology, Inc. (CHRS) Q3 2025 Earnings Call Transcript

Coherus Oncology, Inc. ( CHRS ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Dennis Lanfear - Chairman, President & CEO Theresa Lavallee - Chief Development Officer & Chairman of Scientific Advisory Board Rosh Dias Sameer Goregaoker Bryan McMichael - Chief Financial Officer Rosh Dias - Chief Medical Officer Conference Call Participants Michael Nedelcovych - TD Cowen, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Jason Mccarthy - Maxim Group LLC, Research Division Nick Quartapella - Robert W. Baird & Co. Incorporated, Research Division Douglas Tsao - H.C.

Seeking Alpha • Nov 7, 2025